Crux Wealth Advisors Buys Shares of 3,335 Stryker Co. (NYSE:SYK)

Crux Wealth Advisors acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,335 shares of the medical technology company's stock, valued at approximately $1,201,000.

Several other hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Stryker by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after buying an additional 252,188 shares in the last quarter. FMR LLC grew its position in shares of Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares during the period. Geode Capital Management LLC lifted its stake in Stryker by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Norges Bank acquired a new position in shares of Stryker during the fourth quarter valued at approximately $1,710,744,000. Finally, Invesco Ltd. lifted its holdings in Stryker by 15.3% in the 4th quarter. Invesco Ltd. now owns 2,007,105 shares of the medical technology company's stock valued at $722,658,000 after purchasing an additional 266,587 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Price Performance

SYK stock traded down $6.54 during midday trading on Tuesday, hitting $346.88. 1,670,378 shares of the stock were exchanged, compared to its average volume of 1,361,566. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market cap of $132.40 billion, a price-to-earnings ratio of 44.70, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock's 50-day moving average price is $374.63 and its 200-day moving average price is $373.58.

Remove Ads

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business earned $3.46 earnings per share. Research analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. Stryker's dividend payout ratio is presently 43.30%.

Analyst Ratings Changes

Several analysts recently issued reports on SYK shares. Canaccord Genuity Group upped their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Citigroup reaffirmed a "buy" rating and issued a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Finally, Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $423.05.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.